|PDII -- Exotistan Stock|| |
USD 0.53 0.53 9,223,372,036,855%
Given the investment horizon of 30 days, and your above average risk tolerance our recommendation regarding Interpace Diagnostics Group is 'Strong Sell'
. Macroaxis provides Interpace Diagnostics buy hold or sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding PDII positions. The advice algorithm takes into account all of Interpace Diagnostics available fundamental, technical, and predictive indicators you will find on this site. The advice is provided from PDII buy-and-hold prospective. Additionally take a look at Interpace Diagnostics Analyst Recommendation
to compare Macroaxis Buy or Sell Recommendation with current analyst consensus.
For the selected time horizon Interpace Diagnostics Group has a risk adjusted performance of 0.0, jensen alpha of 0.0, total risk alpha of 0.0, sortino ratio of 0.0 and treynor ratio of 0.0
We provide buy, hold, or sell suggestion to complement the regular expert consensus
on Interpace Diagnostics. Our dynamic recommendation engine utilizes multi - dimensional algorithm to analyze the organization potential to grow using all technical and fundamental data available at the time. To make sure Interpace Diagnostics Group is not overpriced, please check out all Interpace Diagnostics fundamentals including its Net Income
, Number of Employees
, Z Score
, as well as the relationship
between Debt to Equity
and Retained Earnings
Interpace Diagnostics Greeks
Interpace Diagnostics Volatility Alert
Interpace Diagnostics Group exhibits very low volatility with skewness of 0.0 and kurtosis of 0.0. However, we advise investors to further study Interpace Diagnostics Group technical indicators to make sure all market info is available and is reliable. Interpace Diagnostics Group is a potential penny stock. Although Interpace Diagnostics may be in fact a good instrument to invest, many penny stocks are speculative in nature and are subject to artificial stock hype. Please make sure you totally understand upside potential and downside risk of investing in Interpace Diagnostics Group. We encourage investors to look for the signals such us email spams, message board hypes, claims of breakthroughs, volume upswings,sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on this equity instrument if you perfectly time your entry and exit. However, remember that penny stocks that has been the subject of an artificial hype usually unable to maintain its increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The one and only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.
Interpace Diagnostics Fundamental Vs Peers
|Interpace Diagnostics generates negative expected return over the last 30 days|
|Interpace Diagnostics has some characteristics of a very speculative penny stock|
|Interpace Diagnostics has high likelihood to experience some financial distress in the next 2 years|
|The company reported previous year revenue of 140.12 M. Net Loss for the year was (19.75 M) with profit before overhead, payroll, taxes, and interest of 18.54 M. |
|PDI INC currently holds about 9.4 M in cash with (21.95 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.56 which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
|Roughly 61.0% of the company outstanding shares are owned by corporate insiders|
|Latest headline from stanleybusinessdaily.com: Interpace Diagnostics Group, Inc. Has Reported Sales Growth of 0.27485 Year Over Year|